RJA
LXRX icon

Raymond James & Associates’s Lexicon Pharmaceuticals LXRX Stock Holding History

Raymond James & Associates’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$17.1K Hold
10,912
– – ﹤0.01% 3956
2024
Q2 		$18.3K Buy
10,912
+71
+0.7% +$127 ﹤0.01% 3896
2024
Q1 		$26K Hold
10,841
– – ﹤0.01% 3855
2023
Q4 		$16.6K Hold
10,841
– – ﹤0.01% 3777
2023
Q3 		$11.8K Sell
10,841
-232
-2% -$407 ﹤0.01% 3756
2023
Q2 		$25.4K Buy
+11,073
New +$29.4K ﹤0.01% 3757
2017
Q4 		– Sell
-33,829
Closed -$416K – 3488
2017
Q3 		$416K Sell
33,829
-1,025
-3% -$15.1K ﹤0.01% 2592
2017
Q2 		$573K Buy
34,854
+3,418
+11% +$52.9K ﹤0.01% 2333
2017
Q1 		$451K Buy
31,436
+1,053
+3% +$15.6K ﹤0.01% 2449
2016
Q4 		$420K Buy
30,383
+2,150
+8% +$34.5K ﹤0.01% 2436
2016
Q3 		$510K Buy
28,233
+6,293
+29% +$101K ﹤0.01% 2272
2016
Q2 		$315K Sell
21,940
-33
-0.2% -$448 ﹤0.01% 2385
2016
Q1 		$263K Buy
+21,973
New +$230K ﹤0.01% 2420

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Raymond James & Associates's LXRX Position: Q3 2024 in Review

Raymond James & Associates held its Lexicon Pharmaceuticals (LXRX) position steady in Q3 2024 at 10,912 shares worth $17.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3956.

Raymond James & Associates first reported a position in LXRX in Q1 2016 and has held it in 13 quarters since. The position peaked at $573K in Q2 2017. 137 funds tracked by Wall St. Rank hold LXRX as of Q3 2024.

  • Raymond James & Associates held 10,912 shares of Lexicon Pharmaceuticals worth $17.1K as of Q3 2024.
  • Raymond James & Associates left its Lexicon Pharmaceuticals share count unchanged in Q3 2024.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3956 holding.
  • Raymond James & Associates first reported a position in Lexicon Pharmaceuticals in Q1 2016 and has held it in 13 quarters since.
  • Raymond James & Associates's Lexicon Pharmaceuticals position peaked at $573K in Q2 2017.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.